title: HIV vaccine: Can it be developed in the 21st century?
abstract: HIV infection is a major public health problem especially in the developing countries. Once a person infects with HIV, it remained infected for lifelong. The advanced stage developed after 10-15 y of HIV infection that stage is called acquired immunodeficiency syndrome (AIDS). From 1990 to 2000 the number of people living with HIV rose from 8 million to 27 million; since the beginning of the HIV/AIDS epidemic, AIDS has claimed almost 39million lives so far. Till now, there is no cure for HIV infection; however, after the introduction of effective treatment with antiretroviral (ARV) drugs the HIV individual can enjoy healthy and productive lives. Vaccine is safe and cost-effective to prevent illness, impairment, disability and death. Like other vaccines, a preventive HIV vaccine could help save millions of lives. All vaccines work the same way i.e. the antigen stimulate the immune system and develop antibodies. The ultimate goal is to develop a safe and effective vaccine that protects people worldwide from getting infected with HIV. However, some school of thought that vaccine may protects only some HIV people, it could have a major impact on the rates of transmission of HIV and this will help in control of epidemic, especially in populations where high rate of HIV transmission. In the past, some scientist doubted on the development of an effective polio vaccine, but now we are near to eradicate the polio from the world this is possible because of successful vaccination programmes. HIV vaccine research is aided by the not-for-profit International AIDS/HIV vaccine Initiative (IAVI), which helps to support and coordinate vaccine research, development, policy and advocacy around the world. Although the challenges for scientist are intimidating but scientists remain hopeful that they can develop safe and effective HIV vaccines for patients in future.
authors.affiliation: a Department of Community Medicine , Pt. B.D. Sharma PGIMS , Rohtak , Haryana , India.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Verma
authors.affiliation: a Department of Community Medicine , Pt. B.D. Sharma PGIMS , Rohtak , Haryana , India.
authors.forename: Pardeep
authors.initials: P
authors.lastname: Khanna
authors.affiliation: b Department of Community Medicine ; SHKM Goverment Medical College ; Nalhar, Mewat , Haryana , India.
authors.forename: Suraj
authors.initials: S
authors.lastname: Chawla
authors.affiliation: c Department of Pediatrics ; LHMC ; New Delhi , India.
authors.forename: Mukesh
authors.initials: M
authors.lastname: Dhankar
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D055808:Drug Discovery / Q000458:organization & administration / Q000639:trends*; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans
chemical_list: D016915:AIDS Vaccines
keywords: AIDS; HIV; advocacy; clinical trial; vaccine